pivekimab sunirine
immunogen,milestone pharma
['cadenza', 'pivekimab', 'immunogen ', '$imgn']
immunogen presents updated findings from phase 2 cadenza trial of pivekimab sunirine in bpdcn patients at eha 2023 congress. $imgn #positive 
Real-time news analysis & sentiment scoring for the stocks in the Nasdaq100
Powered by @streetbeat_com of @SP500Tracker
Disclosure: https://t.co/ixCFGXlG3M